Overcoming the blood brain barrier in glioblastoma: Status and future perspective
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology
Reference40 articles.
1. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019;Ostrom;Neuro Oncol,2022
2. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial;Stupp;JAMA,2017
3. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial;Herrlinger;Lancet,2019
4. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter;Lim;Neuro Oncol,2022
5. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial;Omuro;Neuro Oncol,2023
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. “Quinoline Analogues and Nanocarrier Systems: A Dual Approach to Anti-Tubercular Therapy";European Journal of Medicinal Chemistry Reports;2024-09
2. Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review;Cancer Chemotherapy and Pharmacology;2024-06-25
3. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas;Current Treatment Options in Oncology;2024-06-19
4. Interneurons that BiTE: Harnessing the migratory capacity of cortical inhibitory interneuron precursors to treat high-grade glioma;2024-05-02
5. Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities;International Journal of Biological Macromolecules;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3